From @jacionline.bsky.social 🫁
#Tezepelumab is associated with clinical remission at week 52 in about one-third of patients with severe #asthma and has favorable safety and tolerability. #PulmSky
www.pulmonologyadvisor.com
Tezepelumab led to clinical remission at 1 year in about a third of patients with severe asthma and had favorable safety and tolerability.
